MichaelJBurkeMD

PubMed

• 21 citations
  Concomitant use of vagus nerve stimulation and electroconvulsive therapy for treatment-resistant depression.
  Michael J. Burke, Mustafa M. Husain> ;The Journal of ECT. 2006 Sep 1
• 24 citations
  Number of risk genotypes is a risk factor for major depressive disorder: a case control study
  Holly A. Garriock, Pedro L. Delgado, Mitchel A. Kling, Linda L. Carpenter, Michael J. Burke, William J. Burke, Thomas L Schwartz, Lauren B. Marangell, Mustafa M. Husai...> ;Behavioral and Brain Functions. 2006 Jul 5
• 167 citations
  Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression.
  David L. Dunner, A. John Rush, James M. Russell, Michael J. Burke, Stacy Woodard, Peggy Wingard, John J.B. Allen> ;The Journal of Clinical Psychiatry. 2006 May 15
• 12 citations
  Trends in Undergraduate Medical Education: Clinical Clerkship Learning Objectives
  Michael J. Burke, Amy C. Brodkey> ;Academic Psychiatry. 2006 Mar 1
• 231 citations
  A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression.
  Mark S. George, A. John Rush, Lauren B. Marangell, Harold A. Sackeim, Stephen K. Brannan, Sonia M. Davis, Robert H Howland, Mitchel A. Kling, Francisco A. Moreno, Barr...> ;Biological Psychiatry. 2005 Sep 1
• 257 citations
  Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study
  A. John Rush, Harold A. Sackeim, Lauren B. Marangell, Mark S. George, Stephen K. Brannan, Sonia M. Davis, Phil Lavori, Robert H Howland, Mitchel A. Kling, Barry R. Rit...> ;Biological Psychiatry. 2005 Sep 1
• 16 citations
  Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia.
  Anne T. Harvey, David A. Flockhart, J. Christopher Gorski, David J. Greenblatt, Michael J. Burke, Steve Werder, Sheldon H. Preskorn> ;Journal of Clinical Pharmacology. 2004 Oct 1
• 6 citations
  A comparison of the MCMI-III personality disorder and modifier indices with the MMPI-2 clinical and validity scales.
  Mike R. Schoenberg, Darwin Dorr, C. Don Morgan, Michael J. Burke> ;Journal of Personality Assessment. 2004 Jun 1
• 5 citations
  Implementing a systematic course/clerkship peer review process.
  Michael J. Burke, Giulia Bonaminio, Anne Walling> ;Academic Medicine. 2002 Sep 1
• 5 citations
  Overreport on the MCMI-III: concurrent validation with the MMPI-2 using a psychiatric inpatient sample.
  C. Don Morgan, Mike R. Schoenberg, Darwin Dorr, Michael J. Burke> ;Journal of Personality Assessment. 2002 Apr 1
• 9 citations
  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.
  M J Burke, S H Preskorn> ;Clinical Pharmacokinetics. 1999 Aug 1
• 6 citations
  Death due to alcoholic complications in a young woman with a severe eating disorder : A case report
  Mark L. Catterson, Tamara Pryor, Michael J. Burke, C. Don Morgan> ;The International Journal of Eating Disorders. 1997 Apr 1
• 1 citations
  CLINICOECONOMICS IN GEROPSYCHIATRY
  Michael J. Burke> ;The Psychiatric Clinics of North America. 1997 Mar 1
• 3 citations
  Pharmacokinetics of the newer antidepressants.
  Michael J. Burke, Anne T. Harvey, Sheldon H. Preskorn> ;The American Journal of Medicine. 1996 Jan 1
• 10 citations
  Comment on: the serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease.
  Anne T. Harvey, Michael J. Burke> ;The American Journal of Emergency Medicine. 1995 Sep 1
• 16 citations
  Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder.
  Michael J. Burke, Silkey B, Sheldon H. Preskorn> ;The Journal of Clinical Psychiatry. 1994 Sep 1
• 44 citations
  Therapeutic drug monitoring. Principles and practice.
  Sheldon H. Preskorn, Michael J. Burke, Gary A. Fast> ;The Psychiatric Clinics of North America. 1993 Sep 1
• 39 citations
  Somatic therapy for major depressive disorder: selection of an antidepressant.
  Sheldon H. Preskorn, Michael J. Burke> ;The Journal of Clinical Psychiatry. 1992 Sep 1
• Join now to see all

Lectures

• Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018